NCT03756129View on ClinicalTrials.gov

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 8, 2019

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions
Depressive Disorder, Treatment-Resistant
Interventions
DRUG

MIJ821

Different dosages and different regimen for MIJ821

DRUG

Placebo

Infusion

DRUG

Ketamine

Infusion

Trial Locations (12)

20850

Novartis Investigative Site, Rockville

30331

Novartis Investigative Site, Atlanta

34201

Novartis Investigative Site, Bradenton

35294

Novartis Investigative Site, Birmingham

60076

Novartis Investigative Site, Skokie

92845

Novartis Investigative Site, Garden Grove

94607

Novartis Investigative Site, Oakland

08009

Novartis Investigative Site, Berlin

07120

Novartis Investigative Site, Palma de Mallorca

01004

Novartis Investigative Site, Vitoria-Gasteiz

08036

Novartis Investigative Site, Barcelona

08006

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY